Sigyn Therapeutics, Inc. (OTCQB: SIGY) disclosed today that a study published in Science Translational Medicine and highlighted by Scientific American provides clinical evidence of blood-brain barrier disruption and chronic inflammation in living individuals suspected of having Chronic Traumatic Encephalopathy (CTE). The findings support the potential application of the company's CardioDialysis™ technology in treating neuroinflammatory conditions.
On March 21, Scientific American published an article titled 'Brain’s Protective Barrier Stays Leaky for Years after Playing Contact Sports,' coinciding with a study in Science Translational Medicine by researchers at Trinity College Dublin. The study reported that the blood-brain barrier may remain compromised and permeable for decades after an athlete's retirement from sports involving repetitive head trauma. In the United States, CTE has been most commonly diagnosed in former NFL players through post-mortem autopsy.
When the integrity of the blood-brain barrier is compromised, inflammatory molecules and pathogenic toxins in the bloodstream can enter the brain, triggering neuroinflammation that leads to abnormal accumulation of tau protein, a hallmark of CTE. The researchers observed that former athletes appeared to exist in a persistent state of chronic hyperinflammation.
The Trinity study adds to evidence that systemic inflammation is a key driver of neuroinflammation in disorders such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. Given its broad-spectrum mechanism, CardioDialysis is uniquely positioned to emerge as a potential adjunct therapy for neuroinflammatory conditions. The technology enables continuous clearance of inflammatory and pathogenic molecules from the bloodstream.
Sigyn Therapeutics is pursuing a strategic transaction focused on using CardioDialysis to reduce systemic inflammation associated with traumatic brain injury (TBI). The company's lead clinical indication remains cardiovascular disease, the leading cause of death worldwide.
'It is becoming increasingly clear that CardioDialysis may play a meaningful role to slow the progression of neuroinflammatory disorders, particularly in high-risk individuals or during the early stages of disease,' stated Sigyn Therapeutics CEO Jim Joyce. 'The dual reduction of inflammatory and pathogenic factors from the bloodstream could help stabilize the blood-brain barrier, which would limit the leakage of harmful molecules into the brain.'
CardioDialysis is a next-generation blood purification technology that integrates plasma separation and therapeutic adsorption within a single device. Beyond cardiovascular disease, it is being explored for sepsis, viral infections, and neurological disorders associated with systemic inflammation.
